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Dengue is a mosquito-borne viral disease that is a major public health problem worldwide. In 2004, the Pediatric
Dengue Cohort Study was established in Managua, Nicaragua, to study the natural history and transmission of
dengue in children. Here, the authors describe the study design, methods, and results from 2004 to 2008. Initially,
3,721 children 2–9 years of age were recruited through door-to-door visits. Each year, new children aged 2 years
are enrolled in the study to maintain the age structure. Children are provided with medical care through the study,
and data from each medical visit are recorded on systematic study forms. All participants presenting with sus-
pected dengue or undifferentiated fever are tested for dengue by virologic, serologic, and molecular biologic
assays. Yearly blood samples are collected to detect inapparent dengue virus infections. Numerous information
and communications technologies are used to manage study data, track samples, and maintain quality control,
including personal data assistants, barcodes, global information systems, and ﬁngerprint scans. Close collabora-
tion with the Nicaraguan Ministry of Health and use of almost entirely local staff are essential components for
success. This study is providing critical data on the epidemiology and transmission of dengue in the Americas
needed for future vaccine trials.
Central America; cohort studies; dengue; information systems; methods; Nicaragua
Abbreviations: CBC, complete blood count; DENV, dengue virus; GPS, global positioning system; HCSFV, Health Center So ´c-
rates FloresVivas.HIMJR,Hospital Infantil ManueldeJesu ´s Rivera; PDA,personaldataassistant; RT-PCR,reversetranscriptase-
polymerase chain reaction.
Dengue virus (DENV) causes the most prevalent
mosquito-borne viral illness in humans, with an estimated
50 million cases occurring annually in tropical and subtrop-
ical countries (1). Four serotypes of the virus (DENV-1,
DENV-2, DENV-3, DENV-4) are transmitted by the
domestic, daytime-biting mosquitoes Aedes aegypti and
Ae. albopictus. From 50% to 90% of DENV infections can
be inapparent (2–4). Of those that develop symptoms, most
cases present as undifferentiated fever or classic dengue
fever, a debilitating but self-limiting acute febrile illness
characterized by headache, retroorbital pain, arthralgia, my-
algia, rash, and mild hemorrhagic manifestations. A subset
of dengue cases progress to the potentially lethal dengue
hemorrhagic fever/dengue shock syndrome, characterized
by vascular leakage leading to shock, low platelet counts,
and hemorrhagic manifestations (5). Infection by 1 DENV
serotype provides lifelong immunity against that serotype
but confers only partial and transient protection against sub-
sequent infections with other DENV serotypes (6). Substan-
tial epidemiologic evidence indicates that sequential
infection with different DENV serotypes increases the risk
of dengue hemorrhagic fever/dengue shock syndrome (7).
Currently, the only way to control dengue is by targeting
its mosquito vector through insecticides and elimination of
potential breeding sites. Treatment for dengue is limited to
supportive care. However, a number of vaccines are under
development (8, 9), with several in phase 2 trials. Phase 3
trials are planned over the next few years to test the efﬁcacy
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120 Am J Epidemiol 2009;170:120–129of these vaccines in children. Prior to these trials, further
epidemiologic information is needed about the incidence
and burden of dengue worldwide to design trials with sufﬁ-
cient statistical power while minimizing any potential risks.
Large-scale prospective cohort studies of dengue can pro-
vide these data and prepare for vaccine trials, and these are
needed in both Asia and the Americas, the 2 regions with
greatest dengue activity (1, 10).
The design, logistics, and execution of prospective large-
scale cohort studies are challenging in any setting, but they
can be especially difﬁcult in a developing country where
infrastructure and services may be unreliable or nonexistent.
These challenges include the following: 1) lack of street
names and addresses, 2) low prevalence of telephone owner-
ship by the families of many participants, 3) no reliable
postal system, 4) a proportion of illiterate participants, and 5)
irregular electrical and water services.
A pediatric cohort study following approximately 3,800
children was conducted in Managua, Nicaragua, from 2004
to the present. The objective of the Nicaraguan Pediatric
Dengue Cohort Study is to study the natural history of den-
gue, document its incidence and seroprevalence, character-
ize the symptoms and disease spectrum, collect biologic
samples for immunology and vaccine safety research, and
prepare for a potential phase 2/3 vaccine trial. This paper
describes the methods used to establish and conduct the
Nicaraguan Pediatric Dengue Cohort Study and extend it
to study inﬂuenza and other respiratory diseases, as well
as the information technologies used to overcome logistic
challenges and ensure the high quality of the study.
MATERIALS AND METHODS
Study site and organization
This study is conducted at the Health Center So ´crates
Flores Vivas (HCSFV) in District II of Managua, the capital
of Nicaragua. District II is adjacent to Lake Managua, and
the Health Center serves a population of approximately
60,047. The primary health-care facility is the HCSFV;
study children requiring additional medical attention are
transferred to the study hospital, the National Pediatric Ref-
erence Hospital, Hospital Infantil Manuel de Jesu ´s Rivera
(HIMJR). Clinical laboratory tests are performed in the
HCSFV, while all virologic and serologic tests are per-
formed at the National Virology Laboratory of the Centro
Nacional de Diagno ´stico y Referencia. All study facilities
are part of the Nicaraguan Ministry of Health, and the na-
tional directors of epidemiology, the reference laboratories,
and the health province of Managua sit on the Executive
Committee of the Pediatric Dengue Cohort Study. A formal
agreement (‘‘convenio’’) supporting the study is signed by
the Minister of Health and the principal investigator of the
study. Ninety-ﬁve percent of study personnel are Nicara-
guan, and all decisions are made by consensus by a technical
committee composed of Pediatric Dengue Cohort Study site
directors, informatics and quality control directors, the
study coordinator, and the principal investigator. This study
was approved by the institutional review boards at the
University of California, Berkeley, the International Vaccine
Initiative, and the Nicaraguan Ministry of Health (Centro
Nacional de Diagno ´stico y Referencia and HIMJR).
Recruitment
To recruit cohort participants, in August and September
of 2004, study teams performed house-to-house visits in
neighborhoods served by the HCSFVand invited all eligible
children to participate. Eligibility criteria included the fol-
lowing: 1) age between 2 and 9 years, 2) residence in the
study area, 3) no plan to leave the study area during the
following 3 years, 4) willingness to attend the study clinic
for all medical needs, 5) no immune-compromising condi-
tions, such as current chemotherapy treatment or human
immunodeﬁciency virus positivity, 6) informed parental
consent, and 7) participant assent for children over 5 years
of age. Children were eligible to remain in the study until
the age of 12 years or until they moved from the study area.
To maintain the age structure of the cohort, we recruited
children aged 2 years between July and September of each
year. The initial informed consent applied to the ﬁrst 3 years
of the study; in 2007, study participants aged 11 years or
younger and their families were given the opportunity to
continue for an additional 3 years, and a second informed
consent was performed. In the fourth year of the study,
additional children aged 3–9 years were enrolled to even
out the age distribution.
Enrollment and baseline visit
At enrollment, demographic data are collected, a global
positioning system (GPS) point is taken of the child’s house,
and children are scheduled for a baseline study visit at the
HCSFV, which consists of collection of a clinical history,
additional demographic data, and a blood sample. The child
is issued a study identiﬁcation card with photograph, study
code, and barcode, and a ﬁngerprint scan is performed to aid
in participant identiﬁcation. Families are instructed to bring
the child to the HCSFV at the ﬁrst sign of fever or illness.
Participants are provided with free medical care and labo-
ratory testing through the study. Study physicians and an
ambulance are available 24 hours/day, 365 days/year. Par-
ticipants requiring hospitalization or secondary-level care
are transferred to the study hospital, HIMJR, by study staff.
Data from all medical appointments are collected systemat-
ically on standardized study forms at both the HCSFV and
the HIMJR.
Case surveillance
Upon presentation to the HCSFV, participants identify
themselves at the reception desk. They are then directed
to the study area, where a study nurse measures their height,
weight, and tympanic temperature and records the informa-
tion by using a standardized medical visit form. Study
physicians perform a medical examination and record data
systematically onthe history of the illness andcurrent symp-
toms, consisting of approximately 80 variables including
blood pressure, cardiac and respiratory rates, a second
tympanic temperature measurement, lower and upper
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tors of dehydration, urinary tract symptoms, musculoskele-
tal pain, rashes and other skin abnormalities, hemorrhagic
manifestations, and nutritional status. Data are recorded on
any medical tests ordered and treatments prescribed.
The physician then classiﬁes the patient in 1 of 4 catego-
ries: A, B, C, or D (Figure 1). Patients classiﬁed as category
A meet the World Health Organization’s classiﬁcation
of suspected dengue, namely, an acute febrile illness with
2 or more of the following symptoms or signs: headache,
retroorbital pain, myalgia, arthralgia, rash, hemorrhagic
manifestations, or leucopenia. Patients classiﬁed as category
B display undifferentiated acute febrile illness or febrile
illness without an evident cause. Patients classiﬁed as cate-
gory C are febrile cases with a deﬁned focus, such as pneu-
monia or dysentery. Category D patients are those with
afebrile illnesses, chronic diseases, and accidents.
Category A patients. Category A patients are treated as
suspected dengue cases. An acute blood sample is drawn at
the ﬁrst visit, and an examination is performed. A complete
blood count (CBC) and reverse transcriptase-polymerase
chain reaction (RT-PCR) and virus isolation for DENV are
performed immediately. The child is scheduled for follow-
up visits each day until complete recovery from the illness.
If the child misses an appointment, study staff visit the
child’s home to provide continuing medical care. A conva-
lescent blood sample is collected 14–30 days after the onset
of symptoms for dengue serology tests.
Category B patients. Category B patients are treated as
possible dengue cases and are handled similarly to category
A cases, except that RT-PCR and virus isolation for DENV
are performed retrospectively on the acute sample only if
serologic assays on paired acute- and convalescent-phase
samples indicate a current DENV infection.
Category C and category D patients. CategoryC(febrile)
and category D (afebrile) patients receive medical care and
tests as indicated by their symptoms. In December 2005 and
January 2006 and then from June 2006 to the present, a con-
venience sample of acute blood specimens from about 40%
of category C patients was collected and stored for future
dengue testing.
Field visits
An annual ﬁeld visit is conducted to assess and encourage
participant participation. Study teams attempt to visit each
child at his/her home, which is located by using GPS data. If
the team cannot interview a parent or guardian at the ﬁrst
visit, 2 additional attempts are made. Study teams composed
of 2 ﬁeld staff are preassigned a set of participants to visit,
maps of the location of each team’s set are printed, and the
GPS points and children’s information are downloaded into
hand-held GPS devices. Throughout the day, data are trans-
ferred from the ﬁeld staff’s personal data assistants (PDAs)
to a supervisor’s PDA to prevent data loss and to allow for
multiple updates of the study database throughout the day.
This allows for real-time monitoring, enabling rapid assess-
ment of progress, efﬁcient reassignment of participant visits
when necessary, and effective planning of the next day’s
visits. Questions in the study participation survey elicit in-
formation about attendance to the HCSFV for all illnesses
and use of medical providers outside of the cohort. Periodic
ﬁeldvisitsarealsoconductedtocollectconvalescentsamples,
providefollow-upmedical caretochildrenwhomissappoint-
ments, and check on the status of participants who have not
had contact with the study in the prior 6-month period.
Yearly sample collection
Each July or August, an annual blood sample is collected
to examine the incidence of subclinical DENV infection.
The annual sampling takes place in 2 phases. In the ﬁrst
phase, participants present at the HCSFV, and the annual
sample is collected at a temporary specimen collection cen-
ter in the HCSFV auditorium. Brieﬂy, children are iden-
tiﬁed by identiﬁcation card or ﬁngerprint scanning at the
identiﬁcation and registration station, where barcode labels
Figure 1. Flowchart of case classiﬁcation during initial medical consults of children in the Pediatric Dengue Cohort Study, Managua, Nicaragua,
2004–2008.
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printed. Children continue to a nurses’station where a nurse
uses a barcode scanner-enabled PDA for automatic retrieval
of data and paperless data entry of interview and specimen
information. The nurse draws a blood sample for CBC and
dengue serologic tests. The CBC results are returned to the
parent or guardian within 2 days, and if any abnormalities
are noted (e.g., anemia), appropriate medical follow-up is
scheduled. When they pick up the CBC results, participants
are provided with a study gift of school supplies worth
approximately US $1.00. Test results indicating whether
the child has been infected with DENV during the previous
year are also returned. In the second phase, ﬁeld teams visit
the homes of all participants who did not present to the
HCSFV during the ﬁrst phase. As in ﬁeld visits, households
are located using GPS devices. Each household is visited at
least 3 times in an attempt to locate the participant. After 3
unsuccessful attempts to locate the participant or conﬁrma-
tion that the child no longer lives in the study area, study staff
record the child as lost to follow-up.
Electronic sample tracking
In order to ensure the quality of samples and laboratory
results, a sample-tracking system was developed to handle
the thousands of blood samples processed each year (refer to
Figure 2 for an example of category A samples). All samples
collected in the study are labeled with 2-dimensional bar-
codes, which are appropriately sized for collection, micro-
centrifuge, and cryopreservation tubes. This minimizes input
error and allows real-time sample tracking from collection in
the HCSFV or in the ﬁeld to processing and storage in the
National Virology Laboratory. Barcode labels for sample col-
lection tubes are automatically printed during the year upon
a child’s presentation with illness at the clinical laboratory in
the HCSFV following the scanning of a study identiﬁcation
cardor child’s ﬁngerprint and selection ofthe medical tests to
be performed. When samples are collected in the ﬁeld, bar-
code labels are preprinted prior to the visit. At every step,
from collection of the sample to transport to reception at the
Virology Laboratory, the tubes are scanned, and an automatic
time and date stamp is recorded. Once received at the Virol-
ogy Laboratory, each sample is scanned, at which time bar-
code labels are automatically printed for sample processing
and storage of all aliquots. The sample-tracking system is
used to automatically record the box, rack, and freezer in
which a sample is placed for storage. This system also en-
ables monitoring of sample volume in each aliquot, as the
volume used in every assay is automatically subtracted from
the initial volume. Additionally, the barcoding system
Figure2. Flowchart ofsampleandinformationﬂowfor probabledenguecasesintheLaboratoryInformationManagementSystemof thePediatric
Dengue Cohort Study, Managua, Nicaragua, 2004–2008. CBC, complete blood count; CNDR, Centro Nacional de Diagno ´stico y Referencia; DB,
database; ELISA, enzyme-linked immunosorbent assay; ID, identiﬁcation; IgM, immunoglobulin M; PCR, polymerase chain reaction.
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with the participant’s name, and it alerts the medical staff if
consent has not been obtained, such as for DNA or inﬂuenza,
thereby preventing protocol violations.
Data collection and management
To handle the large amounts of data collected through the
Pediatric Dengue Cohort Study, information technology
staff developed a series of interrelated databases. To ensure
data quality, databases were designed with value-restricted
ﬁelds wherever possible. As many data as possible, such as
study code, date, and time, are entered automatically
through barcode scanning. Additionally, many laboratory
results are electronically transferred to the study databases.
For example, CBC results are concurrently printed for in-
clusion in the patient’s chart and automatically transferred
to the study database. This system reduces data entry errors
and omissions. All data that are manually entered undergo
double data entry. Data from ﬁeld visits, the annual sample,
and clinical histories are collected directly into PDAs,
whose databases are designed with skip patterns to advance
the survey to the appropriate question based on the respond-
ent’s prior answers and with questions to verify responses.
Use of PDAs in data collection ensures that no ﬁelds are
skipped, as is possible with paper-based questionnaires,
thereby minimizing missing data. A series of quality control
queries are run daily on all databases to detect and allow for
real-time correction of any errors that occur. Additionally,
use of PDAs with barcode scanners allows for access to
study databases and the sample tracking system during elec-
trical power outages. During power outages, essential study
computers, such as those used for barcode printing and data
entry, are maintained by using backup batteries or a small
power generator. A description of the components of the
data management and sample tracking system is located in
Appendix Table 1.
Extension of the cohort
In June 2007, the cohort study was extended to include
investigation of inﬂuenza and other viral respiratory dis-
eases. These were chosen because of the large burden of
respiratory diseases in children in developing countries, lack
of detailed epidemiologic data about these diseases, and
similarities in study design required to investigate viral re-
spiratory diseases and dengue. Initially, the focus was on
inﬂuenza, since numerous commonalities exist that make
the cohort ideal for studying both dengue and inﬂuenza.
Forinstance, both are acute febrile diseases, early symptoms
are similar,andcasesmustpresent soonaftersymptomonset
to enable detection and isolation of viruses. Participants
in the dengue cohort were presented with the opportunity
to participate in the Nicaraguan Inﬂuenza Cohort Study,
Figure 3. Flowchart of participants in the Pediatric Dengue Cohort Study, Managua, Nicaragua, 2004–2008.
124 Kuan et al.
Am J Epidemiol 2009;170:120–129and informed consent procedures were performed. As the
dengue cohort was already established and the infrastructure
was in place, adding other diseases did not require extensive
resources or effort. In fact, the only major additions needed
to establish the Nicaraguan Inﬂuenza Cohort Study were the
collection of a respiratory specimen (nasal and oropharyn-
geal swabs) and laboratory testing for inﬂuenza. Subse-
quently, testing for other respiratory viruses, including
respiratory syncytial virus, parainﬂuenza viruses 1–3,
human metapneumovirus, adenoviruses, and rhinoviruses,
was initiated by using the respiratory samples.
Laboratory assays
An acute case is considered positive for dengue if 1)
dengue virus (DENV) is isolated in C6/36 Ae. albopictus
cells (11) and serotyped by RT-PCR (12), 2) DENV RNA is
detected by RT-PCR (12, 13) after extraction from serum
samples by using the QIAamp Viral RNA Mini Kit (Qiagen,
Valencia, California), 3) seroconversion is demonstrated by
using acute and convalescent paired sera by a DENV-
speciﬁc immunoglobulin M capture enzyme-linked immu-
nosorbent assay (14), and/or 4) antibody titer by inhibition
enzyme-linked immunosorbent assay (2, 15) demonstrates
a 4-fold or greater increase in titer in paired acute and con-
valescent sera as calculated by using the Reed-Muench
method (16). Those whose paired annual samples demon-
strate seroconversion or an increase in DENV-speciﬁc anti-
body titer during the year, but who have not had an
identiﬁable febrile episode associated with acute DENV in-
fection, are considered ‘‘inapparent DENV infections.’’
RESULTS
In the ﬁrst year of the dengue cohort study, 3,721 children
were enrolled during an intensive 5-week period that began
on August 30, 2004. In subsequent years, all new partici-
pants were enrolled during a recruitment period in July or
August that typically spanned 4–6 weeks. During the ﬁrst
4 years of the study (August 2004–July 2008), a total of
4,742 children participated, with yearly participation rang-
ing from 3,693 to 3,795 children (Figure 3). The geographic
distribution of participants is shown in Figure 4, and their
baseline characteristics by year are shown in Table 1. Over
the course of the study, 821 (17.3%) children were lost to
follow-up, 245 (5.2%) children were withdrawn from the
Figure 4. Map of study area and distribution of cohort participants in the Pediatric Dengue Cohort Study, Managua, Nicaragua, 2004–2008. C/S
Socrates Flores, Centro de Salud So ´crates Flores Vivas.
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end of the ﬁrst 3 years (Figure 3). Yearly loss to follow-up
ranged from 4.3% to 7.1%. The majority of children lost to
follow-up (n ¼ 533, 64.9%) had moved and could not be
located. Children were withdrawn from the study by study
personnel if theymoved from the study area, reached the age
of 12 years, or failed to follow study procedures, or if their
parents requested withdrawal. Of the 289 children who were
not enrolled again in the study, 262 (90.7%) had reached the
age of 12 years and did not qualify to continue participation.
Participants attended 51,609 appointments at the study
clinic (Table 2). A vast majority (91.9%) of participants
have attended HCSFV for medical attention for 1 or more
illnesses. The median number of visits per child was 8
(range, 0–123 visits). Ninety-four percent of all febrile ill-
nesses (categories A, B, and C) and 97% of possible dengue
cases (categories A and B) presented within the ﬁrst 3 days
of illness. There were 1,600 suspected dengue cases, of
which 1,504 (94%) provided a convalescent sample.
In a satisfaction survey of 3,121 (85%) of the cohort
participants, 2,990 (96%) rated the medical attention re-
ceived through the study as excellent or very good. Of the
3,251 children who qualiﬁed for reenrollment in the study at
the end of the ﬁrst 3-year period, only 27 (0.8%) chose not to
reenroll. In yearly participation surveys, 1.7%–2.5% (aver-
age, 2.1%) of participants reported having attended a health-
care provider outside of the study, and 0.8%–6.1% (average,
2.8%) reported having had an illness and not attending any
medical provider (Table 3). The most common reasons for
not seeking medical care included brief duration of illness
(<12 hours) and relief of symptoms upon self-medication
with over-the-counter pain or cold medications.
Uptake of the Nicaragua Inﬂuenza Cohort Study was
high, with 4,132 of 4,178 (99%) eligible subjects choosing
Table 1. Characteristics of Cohort Participants at the Beginning of Each Study Year in the
Pediatric Dengue Cohort Study, Managua, Nicaragua, 2004–2008
Year 1
(N 5 3,721)
Year 2
(N 5 3,695)
Year 3
(N 5 3,795)
Year 4
(N 5 3,693)
No. % No. % No. % No. %
Sex
Female 1,827 49.1 1,820 49.3 1,870 49.3 1,829 49.5
Male 1,894 50.9 1,875 50.7 1,925 50.7 1,864 50.5
Age, years
2 461 12.4 251 6.8 300 7.9 255 6.9
3 500 13.4 419 11.3 247 6.5 364 9.9
4 543 14.6 464 12.6 399 10.5 307 8.3
5 476 12.8 501 13.6 432 11.4 376 10.2
6 453 12.2 436 11.8 467 12.3 401 10.9
7 477 12.8 428 11.6 423 11.1 436 11.8
8 430 11.6 435 11.8 407 10.7 394 10.7
9 357 9.6 399 10.8 404 10.6 370 10.0
10 24 0.6 340 9.2 368 9.7 370 10.0
11 NA 22 0.6 326 8.6 338 9.2
12 NA NA 22 0.6 82 2.2
Abbreviation: NA, not applicable.
Table 2. Medical Consults of Participants by Year in the Pediatric Dengue Cohort Study,
Managua, Nicaragua, 2004–2008
Year 1
(N 5 11,396)
Year 2
(N 5 12,851)
Year 3
(N 5 13,755)
Year 4
(N 5 13,607)
No. % No. % No. % No. %
Type
Primary 8,463 74.3 9,148 71.2 10,512 76.4 10,127 74.4
Follow-up 2,933 25.7 3,703 28.8 3,243 23.6 3,480 25.6
Case classiﬁcation
Category A 756 6.6 1,451 11.3 772 5.6 763 5.6
Category B 424 3.7 1,182 9.2 979 7.1 846 6.2
Category C 4,854 42.6 4,235 32.9 5,532 40.2 5,181 38.1
Category D 5,362 47.1 5,983 46.6 6,472 47.1 6,817 50.1
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decrease in participation or in the quality of the dengue
study was observed. In fact, more participants presented to
the HCSFV earlier after symptom onset when compared
with the 3 prior years, with the mean days post-symptom
onset at presentation of 1.77 days in 2007–2008 compared
with 2.13 days in 2004–2007 (P ¼ 0.03).
DISCUSSION
In this paper, we describe the study design and methods
used to establish and conduct the Pediatric Dengue Cohort
Study. This study is the ﬁrst large-scale prospective cohort
study in the Americas to determine the incidence rate of
dengue and DENV infection over multiple years. It has
also allowed the establishment of infrastructure necessary
for high-quality clinical studies and trials, including
informatics and quality control systems and experienced
Nicaraguan personnel. Expansion of the study to include
inﬂuenza and viral respiratory diseases was possible with
minimal additional cost and has provided keyepidemiologic
and virologic data about these diseases in Nicaragua, as well
as increased beneﬁt to study participants.
One unique aspect of the study is the extensive, low-cost,
customized informatics system that was developed to ensure
study quality using inexpensive software (17). Implementa-
tion of information technologies in the Pediatric Dengue
Cohort Study has permitted greater efﬁciency and quality
of data collection, allowing investigators to overcome many
of the challenges of performing research in a resource-
limited setting. Speciﬁcally, use of barcodes and PDAs
provided real-time access to study data, allowing constant
monitoring to ensure data quality and completeness. GPS
data greatly facilitated daily planning and coordination of
ﬁeld visits, thereby improving efﬁciency and decreasing
cost. Barcodes and ﬁngerprint scans dramatically reduced
the amount of time required to locate and retrieve medical
charts, thus reducing waiting time and improving patient
ﬂow (18).
Participation was high throughout the 4 years of the study,
as evidenced by the large number of medical visits, the high
percentage (94%) of children that attended a convalescent
visit, and low loss to follow-up. Compliance was also very
high, as demonstrated by the fact that 94% of children with
fever attended the HCSFV within the ﬁrst 3 days of illness,
and few children reported having sought medical care out-
side of the HCSFV. The high participation rates can be
attributed to overall satisfaction with the services provided
by the cohort study, supported by the extremely high accep-
tance rate (99%) of continuing participation in the study.
The addition of inﬂuenza and other viral respiratory dis-
eases was widely accepted by cohort participants, as evi-
denced by the 99% acceptance rate of enrolling in the
inﬂuenza study, and did not negatively impact the dengue
study. These additions enhanced the beneﬁts to both partic-
ipants and the Nicaraguan peoplewith minimal extra burden
on the participants. Incorporation of these additional studies
by the established cohort was efﬁcient and cost-effective,
requiring a fraction of the resources that a separate cohort
would require, and it has yielded critical information about
the burden and seasonality of viral respiratory diseases in
tropical developing countries and allowed establishment of
essential laboratory diagnostic capacity for these diseases
in the Ministry of Health (19) (A. Gordon, A. Balmaseda,
E. Harris, unpublished data).
Close collaboration with the Ministry of Health was vital
to the success of the project (20). By working within the
Ministry of Health and its facilities in a sustainable manner
and not setting up a separate study clinic and laboratory, the
study not only beneﬁtted participants and study personnel
but also improved the public health infrastructure substan-
tially, bringing physical renovations and basic amenities to
the study health center and hospital. Likewise, improve-
ments to the National Virology Laboratory indirectly
beneﬁted the Nicaraguan population. In addition, use of
almost entirely local staff and coinvestigators increased
the acceptability of the project while also training Nicara-
guan scientists and public health professionals.
In summary, local ‘‘ownership’’ and the use of informa-
tion technologies were vital to the implementation, conduct,
and high quality of the Pediatric Dengue Cohort Study. The
study design allowed for the addition of detailed surveil-
lance for other diseases, such as inﬂuenza, in an efﬁcient
and cost-effective manner. Importantly, close collaboration
with the Nicaraguan Ministry of Health and a shared
decision-making process, together with almost entirely
Nicaraguan study personnel, have ensured local beneﬁt
and a lasting impact of the study. Altogether, this has re-
sulted in international recognition of Nicaragua as a Center
of Excellence for dengue research and epidemiology. Fi-
nally, this study is providing key information, including in-
cidence data that will be presented in future reports, needed
for the design and conduct of dengue vaccine trials in the
Americas.
Table 3. Results of Participation Survey by Year in the Pediatric Dengue Cohort Study,
Managua, Nicaragua, 2004–2008
Year 1
(N 5 3,721)
Year 2
(N 5 3,695)
Year 3
(N 5 3,795)
Year 4
(N 5 3,693)
No. % No. % No. % No. %
Participated in survey 2,937 78.9 3,121 84.5 3,196 84.2 3,351 90.7
Had a fever and consulted
other health-care provider
72 2.5 62 2.0 72 2.3 56 1.7
Had a fever and did not
consult a medical provider
49 1.7 78 2.5 195 6.1 28 0.8
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Appendix Table 1. Components of the Customized, Low-Cost Informatics System Used in the Pediatric Dengue Cohort Study, Managua,
Nicaragua, 2004–2008
Function Components
Data entry and management Hardware
Computers
MS9520 Voyager hand-held scanners (Metrologic, West Deptford, New Jersey) for scanning barcodes
Opticon LG2 2D (Opticon, Inc., Orangeburg, New York) for scanning barcodes with automatic time
stamp and mobile tracking
Software
Microsoft Access (Microsoft Corporation, Seattle, Washington) as the primary database
management system
EpiInfo (Centers for Disease Control and Prevention, Atlanta, Georgia) for double data-entry check
Identiﬁcation of participants Hardware
U.are.U. 4000 ﬁngerprint scanner (Digital Personna, Redwood City, California)
Software
Veriﬁnger 4.2 SDK (Neurotechnologija, Vilnius, Lithuania) for ﬁngerprint scanning
Print Studio Professional 2.0 software (Jolly Technologies, San Carlos, California) for printing
identiﬁcation cards with barcodes
Localization of participants’
houses
Hardware
Garmin GPS 60 and Garmin e-Trex hand-held GPS devices (Garmin, Olathe, Kansas)
Software
Mapsource (Garmin, Olathe, Kansas) for downloading points from GPS devices
ArcView (ESRI, Redlands, California) for analyzing geographic information to search for and
locate children in their home and for planning of ﬁeld activities
Mobile data access
and storage
Hardware
SPT 1550 with integrated barcode scanner (Symbol, Oakland, California)
Palm Tungston (Palm, Sunnyvale, California) with Plug-N-Scan barcode kit (Portable Technology
Solutions, LLC, Calverton, New York)
Rechargeable batteries and chargers
Software
Palm OS 4.1 or higher (Palm, Sunnyvale, California)
Pendragon Forms 5.0 (Pendragon Software Corporation, Libertyville, Illinois) for PDA databases and
user interface of PDA databases
Hand-held user licenses
Barcode printing Hardware
TLP 2844 thermal transfer printer, 5095 universal resin ribbons, Polypro 1000 labels for labeling
paperwork and blood collection tubes, and Cryocool 3000 labels for labeling Eppendorf tubes and
cryovials (Zebra, Vernon Hills, Illinois)
Software
Print Studio Professional 2.0 software (Jolly Technologies, San Carlos, California) for barcode printing
using Microsoft Access databases
Visual Basic 6.0 (Microsoft Corporation, Seattle, Washington) for creating tables used to encode
study information into barcodes
Automatic entry of laboratory
results
Hardware
Machine-speciﬁc cables for connecting laboratory equipment to computers
Software
Visual Basic 6.0 (Microsoft Corporation, Seattle, Washington) to manage the PC serial port connector
Abbreviations: GPS, global positioning system; PC, personal computer; PDA, personal data assistant.
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